<DOC>
	<DOCNO>NCT00063219</DOCNO>
	<brief_summary>This non-randomized , open-label clinical trial design determine safety clinical activity new chemotherapeutic agent , MAC-321 , give intravenously patient non-small cell lung cancer . Clinical activity evaluate determine percentage patient objective tumor response treatment MAC-321 . Patients must previously treat platinum-containing chemotherapy regimen . A total 96 patient enrolled trial . Eligible patient receive MAC-321 intravenously every 3 week total 6 course treatment . All patient receive MAC-321 dose . MAC-321 experimental drug , offer outside research trial .</brief_summary>
	<brief_title>Study Evaluating MAC-321 Non-small Cell Lung Cancer Refractory Platinum-based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Recurrence nonsmall cell lung cancer least 1 prior chemotherapy regimen contain platinum agent Recovery acute side effect prior therapy ( exception hair loss ) Adequate bone marrow , liver , kidney function More 2 prior chemotherapy regimens treatment advance metastatic nonsmall cell lung cancer . ( Treatment give conjunction surgery include maximum 2 prior regimen ) Radiation therapy , chemotherapy anticancer therapy within 28 day begin study Symptomatic brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Non-Small-Cell Lung Carcinoma</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Cancer Lung</keyword>
</DOC>